EPS growth rate is interpreted as being close to the annualized share price gain of 17% per year. The positive sentiment towards the company is reflected in the share price momentum, which might present an investment opportunity.
Henan Lingrui Pharmaceutical's earnings growth, likely thanks to its high ROE, is admirable. Its ability to raise earnings while paying out most profits as dividends is notable. Continued growth is expected by analysts.